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Abstract. In this report we present the MPI performances of the ORAC molecular
dynamics code on the CRESCO3 cluster for the Fast Switching Double Annihila-
tion method in the determination of drug-receptor dissociation free energies. We
also present some preliminary FS-DAM results on the inhibition of the Myeloid
Cell Leukemia 1 (MCL1) protein using new potent specific inhibitors. MCL1 is a
key apoptosis regulator and its selective inhibition can be of great importance in
cancer therapy.
1 Introduction
In the recent years, thanks to the constant support of the CRESCO infrastructure, we developed a
new massively parallel technology for the computation of the dissociation free energies in drug-receptor
systems, described at the atomistic level. The method, termed Fast Switching Double Annihilation (FS-
DAM) and thoroughly described in Refs[1, 2, 3, 4, 5], is based on a combination of Replica Exchange
with Solute Tempering technique (REST) and non equilibrium (NE) alchemical approach. In contrast to
the mainstream equilibrium alchemical protocols such as FEP/REST[6], in the NE alchemical approach,
the equilibrium sampling is required only at the starting fully coupled bound and bulk states (attainable
using conventional enhanced sampling simulation methods such as REST), thus eliminating altogether
the need for the optimization of the so-called thermodynamic length along the alchemical coordinate as
in equilibrium FEP or Thermodynamic Integration studies.[7] In FS-DAM, the dissociation free energies
are estimated from the distributions of the NE works[8] obtained by launching fast and independent
annihilation trajectories (originated from the configurations harvested in the REST stage) of the bound
ligand and of the ligand in bulk solvent. Most importantly, unlike in FEP, the confidence level in FS-
DAM predictions (assuming no error from the force field), a crucial quantity in a industrial approach,
can be determined very reliably using standard bootstrap analysis on the collection of the NE works. FS-
DAM, implemented in our in-house ORAC code[5], is particularly suited for non uniform memory access
(NUMA) multi-core architectures such as the CRESCOx clusters, relying on a weak scaling parallelism
for REST and NE technologies on the MPI level and enforcing an OpenMP layer for the strong scaling
parallelization of the bonded and non bonded forces within a single shared memory access compute
node.
In this report we examine the performances of FS-DAM on the MPI level as evaluated on the CRESCO3
cluster using the ORAC OpenMP/MPI hybrid code. We also present some important preliminary results
on the inhibition of the apoptosis regulator Myeloid Cell Leukemia 1 protein (MCL1) by a potent recently
discovered[9] indole-amide compound.
∗Corresponding author. E-mail: procacci@unifi.it.
2 MPI perform aces of the FS-DAM on CRESCO3
OpenMP tests for the ORAC (intranode shared memory) have been thoroughly discussed in Ref. [5, 10].
Here we present the performance of the code for the MPI layer only in order to assess the internode
communications overhead in the FS-DAM approach.
As described elsewhere,[5, 10] for each ligand-receptor pair, the computation of the alchemical annihi-
lation free energy via FS-DAM involves two computational step:
i) the acquisition of a Boltzmann sampling of the fully coupled state (the complex and the ligand in
bulk) using Replica Exchange Simulation with solute tempering (hereinafter REST). For such stage, a
simulation time on the target state from few to few tens of ns is acquired by running concurrent multiple
REST batteries in parallel, for a total simulation time of the order of the microsecond.
ii) the fast switching annihilation of the ligand in the complex and in bulk solvent in a swarm of
independent non equilibrium trajectories (hereinafter FS-NE), typically lasting from few tens to few
hundreds of picoseconds for a total simulation time of the order of the microsecond. The selected ligand-
Figure 1: The MCL1-6AL complex [pdb id code 5if4] : The ribbon structure is the MCL1 protein. The
6AK indole ligand is depicted in the bond/stick representation. MCL1 atoms within 4.0 A˚ of the inhibitor are
represented in ball and stick (orange color) along with residue specification (one letter code). Residue numbering
is that of the pdb file 5if4.
receptor complex in this report, provided in the PDB file 5if4[9], is the Myeloid Cell Leukemia 1 (MCL1)
protein in complex with a potent indole-amide inhibitor (indicated with 6AK). The complex is reported
in Figure 2, where we show the main ligand-residue contacts that are involved in binding. The force field
for the atomistic description of the ligand-receptor system is a combination of the AMBER99SB force
field[11] for the protein, GAFF[6] for the 6AK ligand, and the TIP3 model[12] for the solvating water.
For the simulations of any kind, periodic boundary conditions are used while temperature and pressure
are kept constant at 300 K and 1 Atm standardly using a Nose´ thermostat and a Parrinello-Rahman
Lagrangian, respectively.
Figure 2: Left panel; Performance tests for the REST computational stage; the symbol in green corresponds to
the interpolated speed up ratio for a typical value of 64 MPI instances (assuming 6-8 threads on the OpenMP
layer). Right panel: Performance tests for the and FS-NE computational stage. The symbol in green corresponds
to the interpolated speed up ratio for a typical value of 128 MPI instances (assuming 3-6 OpenMP threads).
In the Figures 1 and 2, we report the speed up ratio and parallel efficiency, referred to the MPI layer
only, obtained for the MCL1-6AK protein in complex with an indole-amide inhibitor, a system of 11175
atoms) on the CRESCO3 HPC system. For the REST stage (see Figure 1), we run a REM simulation
lasting 1.545 ps. Simulations were run (using in all cases one OpenMP thread per trajectories ) with
1, 24,48,86,192 and 384 replicas (i.e. MPI processes) for a corresponding total simulation time of 1.545,
37.08, 74.16, 148.32, 296.64 and 593.28 picoseconds. All REST tests were done in an elapsed time
ranging from 270.9 seconds (1 replica) to 279.2 seconds (384 replicas).
For FS-NE (see Figure 2), we launched NE trajectories lasting 0.6 ps. FS-NE parallel simulations were
done producing 1, 24, 48, 96, 192, 384 and 576 independent non communicating trajectories, for a total
simulation time of 0.6, 14.4, 28.8, 57.6, 115,2 , 230.4 and 345.6 picoseconds. All FS-NE tests were done in
an elapsed time ranging from 119.8 to 120.2 seconds. The performances on the MPI level are practically
ideal for both the REST and FS-NE computational stages, in a wide range including 48 (REST) and
128 (FS-NE) processors as required in the MCL1 project. While, expectedly, the embarrassingly parallel
FS-NE computation exhibits no loss whatsoever of parallel efficiency (see the inset plot in Figure 2), in
the REST computation a minor efficiency loss can be barely appreciated with the 384 replicas simulation
running at 97% of parallel efficiency (see the inset plot in Figure 1). This moderate efficient loss in REST
is due the communication overhead during replica exchange attempts. These are normally implemented
each 15 fs (i.e. 103 attempts in total in the test) for all contiguous pairs of replicas and involve a
MPI SEND / MPI RECEIVE couple of three double precision numbers (the REST scale factors) followed
by an MPI BARRIER on all MPI processes.
3 Dissociation Free energy of the MCL1-6AK complex via FS-
DAM
The REST stage for the MCL1-6AK and the 6AK in bulk solvent, featuring about 11000 and 3000 atoms
simulated for a total time of 20 ns in four eight-replicas batteries (according to the scaling protocol
described in Ref [5, 10]) were computed on CRESCO3 (288 cores, 48 on the MPI layer and six on the
OpenMP) in 48 and 13 wall clock hours, respectively, producing about 216/480 configurations sampled
at 300 K and P=1 Atm every 10 ps. From these initial configurations of the bound ad bulk state, we
started the FS-NE stage, by launching in parallel blocks of 48 NE ligand annihilation trajectories in the
same thermodyanamic condition, each engaging 6 cores on the OpenMP layer for a total of 288 cores
jobs on the CRESCO3 facility. The FS-NE stage on the whole collection of 216(complex) and 480 (bulk)
starting states and using different annihilation times (from 90 ps to 720 ps), was completed in about
two wall clock days.
Figure 3: Upper panels: PMF for the annihilation of the ligand in bulk (left) and in the complex( right) obtained
using different annihilation rates. The insets are a zoom of the PMF in the final stages λ ' 1 of the alchemical
parameter λ Lower panel: Work distributions computed at various annihilation rate for the ligand in bulk (left)
and in the complex (right). The corresponding Gaussian distributions, evaluated using the first two moments of
the collection of 480 and 216 FS-NE works (unbound and bound state respectively), are shown in green color.
As discussed in Ref. [3, 4], the ligand annihilation free energy (in bulk and complex) along the alchemical
path was computed using the first two moments (mean µ and variance σ ) of the NE work distribution,
assumed to be normal, i.e.
∆G(λ) = µ(λ)− βσ(λ)
2
2
0 ≤ λ ≤ 1. (1)
where λ is the alchemical parameter with λ = 0 and λ = 1 indicating the fully coupled and fully
decoupled ligand state, respectively. We stress that, in case of Gaussian distribution, Eq. 1 is a
manifestation of the Crooks theorem[13] and as such is an exact equation.
In Figure 3 (bottom panels), we show the final annihilation work distributions evaluated at λ = 1 for the
A6K decoupled ligand using various annihilation rate in bulk and in the complex. The corresponding
superimposed normal distributions computed using the first two moments µ(1) and σ(1) are also show in
the Figure. In all cases, the Gaussian assumption appears to be fully justified. Further evidence comes
from the calculation of higher moments of the distributions (kurthosis and skewness, data not shown)
that are zero within statistical (bootstrap) error in all cases. In the same Figure 3 (upper panels), we
show the annihilation free energy ∆G(λ) or Potential of Mean Force (PMF) for the unbound state (ligand
in bulk) and for the bound state (ligand in the complex) for various annihilation times ranging from
90 to 720 ps (unbound state) and from 180 to 720 ps (bound state). Figure 3 represents a spectacular
demonstration of the validity of the Crooks theorem, Eq. 1 and of the Gaussian assumption. As
prescribed by the Crooks and Jarzynski theorems[13, 14], the invariance of the PMF to changes in the
NE annihilation rate is observed at any λ within statistical (bootstrap) error for the annihilation of
the ligand in bulk. For the annihilation of the ligand in the complex, the dissipation Wdiss = βσ
2/2,
is significantly larger and a bias error[15] of B = βσ2/(2Nw) is observed for λ approaching to 1 (fully
decoupled state). The λ annihilation protocol is, for all rates, such that for 0 ≤ λ ≤ 0.5 the ligand-
environment electrostatic interactions are switched off, while for 0.5 < λ ≤ 1, the ligand-environment
Lennard-Jones interactions potential is brought to zero.
The differences between the two PMFs, for the the annihilation of the ligand in the complex and in bulk,
provides important information on the nature of the binding in the 6AK-MCL1 system. Such difference
is shown in Figure 4 ( duration of the NE 720 ps for both bound and unbound systems) and shows
that the electrostatic interactions slightly disfavors binding while a gain is observed in the dispersive
repulsive (cavity) part. A similar trend was observed also in other cases.[4, 5]
Finally, the dissociation free energy of the 6AK ligand in the MCL1 system is given by the difference
between the annihilation free energies at the alchemical end point λ = 1, i.e. ∆G0 = ∆Gb(1) −
∆Gu(1). The actual value of the ∆G0 must be corrected[3] for a standard state dependent volume
term, RT ln(Vsite/V0) with V0 being the standard state volume, and possibly by a bias error.[15] The
binding site volume, Vsite, can be estimated from the fluctuation of the center of mass distances between
ligand and receptor in the REST equilibrium stage of the complex. In the Table 1, data are summarized.
Annihilation time (ps) ∆Gb ∆Gu RT ln(Vsite/V0) Bias[15] ∆G0
90 - 96.55 ± 0.54 - - -
180 121.34 ± 1.12 95.58 ± 0.44 -2.48 ± 0.1 -1.56 21.7 ± 1.6
360 119.19 ± 1.02 95.88 ± 0.23 -2.48 ± 0.1 -1.02 19.8 ± 1.3
720 117.66 ± 1.01 95.95 ± 0.16 -2.48 ± 0.1 -0.67 18.6 ± 1.2
Table 1: Annihilation free energies [∆Gu (unbound ligand) and ∆Gb (bound ligand) ], volume[3] and bias [15]
corrections and standard dissociation free energies ∆G0 for the 6AK-MCL1 complex. Reported errors have been
evaluated by bootstrap analysis. All energy values are in kcal/mol. The experimental dissociation free energy for
the 6AK-MCL1 complex[9] is below the theoretical limit in the given experimental condition[9] for competitive
binding assay and is termed to be of “picomolar order” and is estimated to be ∆Gexp ≥ 13 kcal/mol.
Figure 4: Difference between the PMF of the ligand in the complex and in bulk along the alchemical
coordinate. The final value ∆PMF(λ = 1) represent the MCL1-6AK dissociation free energy (except
for a standard state volume correction )
4 Conclusion
Using extensive tests on the CRESCO3 facility, we have shown that the ORAC molecular dynamics
code exhibits essentially a linear scaling for thermodynamic parallelism (Replica Exchange and Fast
Switching Non Equilibrium technologies) when implemented on the MPI layer. We have computed,
using the FS-DAM technology, the dissociation constant of the MCL1-6AK constant, confirming the
potency of the inhibitor versus the apoptosis regulator MCL1, with important implication in cancer
therapy. A full paper on the MCL1 inhibition is in currently in preparation.
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